NCT00286468 - Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus. | Biotech Hunter

Enrollment

500

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions

Diabetes Mellitus

Interventions

DRUG

Alogliptin and glyburide

Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.

DRUG

Alogliptin and glyburide

Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.

DRUG

Glyburide

Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.

Trial Locations (68)

Unknown

Birmingham

Peoria

Phoenix

Anaheim

Artesia

Fresno

Los Angeles

Mission Viejo

Northridge

Orange

San Diego

Tustin

Walnut Creek

Denver

Washington D.C.

Cocoa Beach

Kissimmee

Longwood

New Port Richey

Ocala

Ocoee

Saint Cloud

Tampa

Lawrenceville

Honolulu

Idaho Falls

Avon

Evansville

Lafayette

Erlanger

Baltimore

St Louis

Omaha

Berlin

Burlington

Morehead City

Pinehurst

Winston-Salem

Cincinnati

Dayton

Tulsa

Lansdale

West Grove

Charleston

Columbia

Simpsonville

Cookeville

Milan

Corpus Christi

Dallas

San Antonio

Temple

Texarkana

Burlington

Multiple Cities